Causes of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico

Journal of Medical Screening

Volumn 18, Issue 3, 2011, Pages 115-120

  Vela Amieva, Marcela ^a   Ibarra Gonzalez I ^b   Fernandez Lainez C ^a   Monroy Santoyo, S ^a   Guillen Lopez S ^a   Belmont Martinez L ^a   Hernandez Montiel A ^a  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; DELAYED DIAGNOSIS; ENDOCRINOLOGY; EPIDEMIOLOGY; EVALUATION; FEMALE; HOSPITAL; HUMAN; INFANT; MALE; MEXICO; NEWBORN; PATIENT REFERRAL; PHENYLKETONURIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SPECIALIZATION; STANDARD; STATISTICS; TIME;

ADOLESCENT; AGE DISTRIBUTION; CAUSALITY; CHILD; CHILD, PRESCHOOL; DELAYED DIAGNOSIS; ENDOCRINOLOGY; FEMALE; HOSPITALS, SPECIAL; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEXICO; PHENYLKETONURIAS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SPECIALIZATION; TIME FACTORS;

EID: 80655139845     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2011.011028     Document Type: Article

References (34)

1. th edn. New York, NY: McGraw-Hill Inc, 2001:1667-724
2. Acosta PB, Michals Matalon K. Nutrition management of patients with inherited disorders of aromatic amino acid metabolism. In: Acosta PB, ed. Nutrition management of patients with inherited metabolic disorders. Sudbury, MA: Jones and Bartlett Publishers, 2010:119-52
3. Anastasoaie V, Kurzius L, Forbes P, Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab 2008;95:17-20
4. Blau N, van Spronsen JM, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27
5. Van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: is phenylalanine the only possible cause? J Inherit Metab Dis 2009;32:46-51
6. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43
7. US Preventive Services Task Force. Screening for Phenylketonuria (PKU): US Preventive Services Task Force Reaffirmation Recommendation. Ann Fam Med 2008;6:166
8. Carrasco C, Ruiz de Chávez S, Rodríguez-Budelli M, Velázquez A. Cost-benefit analysis of the Mexican Neonatal screening program for inborn errors of metabolism. In: Therrell BL, ed. Advances in Neonatal Screening. Amsterdam: Excerpta Medica, 1987:447-48
9. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:1-202
10. Geelhoed EA, Lewis B, Hounsome D, O'Leary P. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. J Paediatr Child Health 2005;41:575-79 (Pubitemid 43961162)
11. Lara dos Santos L, de Castro Magalhães M, Januário JN, Burle de Aguiar MJ, Santos Carvalho MR. The time has come: a new scene for PKU treatment. Gen Mol Res 2006;5:33-44 (Pubitemid 43326932)
12. Pangkanon S, Charoensiriwatana W, Janejai N, Boonwanich W, Chaisomchit S. Detection of phenylketonuria by the newborn screening program in Thailand. Southeast Asian J Trop Med Public Health 2009;40:525-29
13. Cornejo V, Raimann E, Cabello JF, et al. Past, present and future of newborn screening in Chile. J Inherit Metab Dis 2010; DOI:10.1007/s10545-010- 9165-8
14. Velázquez A, Loera-Luna A, Aguirre BE, Gamboa S, Vargas H, Robles C. Tamiz neonatal para hipotiroidismo congénito y fenilcetonuria. Salud Publica Mex 1994;36:249-56
15. Vela-Amieva M, Gamboa-Cardiel S, Pérez-Andrade ME, Ortiz-Cortés J, González-Contreras CR, Ortega-Velázquez V. Epidemiology of congenital hypothyroidism in Mexico. Salud Publica Mex 2004;46:141-48 (Pubitemid 38765540)
16. Borrajo GJ. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis. 2007;30:466-81 (Pubitemid 47377042)
17. Vela-Amieva M, Belmont-Martínez L, Ibarra-González I, Fernández-Lainez C. Variabilidad interinstitucional del tamiz neonatal en México. Bol Med Hosp Infant Mex 2009;66:431-39
18. Camfield CS, Joseph M, Hurley T, Campbell K, Sanderson S, Camfield PR. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr 2004;145:53-7 (Pubitemid 38962452)
19. Declaration of Common Principles on Centres of Expertise and European Reference Networks for Rare Diseases [Internet] 2008 Nov. 15. Available from: http://www.eurordis.org/sites/default/files/publications/Declaration- Centres%20of%20Expertise-nov08.pdf
20. Therrell BL, Schwartz M, Southard C, Williams D, Hannon WH, Mann MY; PEAS Organizing and Working Groups. Newborn Screening System Performance Evaluation Assessment Scheme (PEAS). Semin Perinatol 2010;34:105-20
21. Lundsjô A, Hagelberg S, Palmér K, Lindblad BS. Amino acid profiles by HPLC after filter paper sampling: 'appropriate technology' for monitoring of nutritional status. Clin Chem Acta 1990;191:201-9
22. McHugh DM, Cameron CA, Abdenur JE, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011; DOI:10.1097/GIM.0b013e31820d5e67
23. Vela-Amieva M, Ibarra-González I, Monroy-Santoyo S, et al. Modelo de atención inicial de la fenilcetonuria y otras hiperfenilalaninemias en el Instituto Nacional de Pediatría. Acta Pediatr Mex 2010;31:297-303
24. Mental and behavioral disorders. In: World Health Organisation, ed. International Statistical Classification of Diseases and Related Health Problems 10th Revision. [Internet] 2007. Available from: http://apps.who.int/ classifications/apps/icd/icd10online/
25. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16-18, 2000. Pediatrics 2001;108:972-82
26. Padilla CD, Krotoski D, Therrell Jr. BL Newborn screening progress in developing countries - overcoming internal barriers. Semin Perinatol 2010;34:145-55
27. Clinical and Laboratory Standards Institute (CLSI): Newborn Screening Follow-up; Approved Guideline: CLSI Document I/LA27-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2006
28. Dougherty FE, Levy H. Present newborn screening for phenylketonuria. MRDD Research Reviews 1999;5:144-49 (Pubitemid 29250125)
29. Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007;92:63-70 (Pubitemid 47361886)
30. Velázquez A, Bilbao G, González-Trujillo JL, et al. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. Hum Genet 1996;97:99-102 (Pubitemid 26002983)
31. Scriver CR. The PAH gene, Phenylketonuria, and the Paradigm Shift. Hum Mutat 2007;28:831-45 (Pubitemid 47579933)
32. Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-6 (Pubitemid 35333132)
33. van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol 2010;6:509-14
34. De Jesús VR, Mei JV, Bell CJ, Hannon WH. Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention. Semin Perinatol 2010;34:125-33